Back to Search Results
Image Place holder

Ardeshir Hakam, MD, MBA

 
Specialty: Pathology
Sub Specialty: Cytopathology
Program: Pathology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Bladder Cancer, Cervical Cancer, Endometrial (Uterine) Cancer, Kidney (Renal Cell) Cancer, Ovarian Cancer, Prostate Cancer, Testicular Cancer, Vaginal Cancer

Ardeshir Hakam, MD, MBA is a Senior Member in Moffitt’s Department of Anatomic Pathology, Director of the Surgical Pathology and Program, Section Head of Gynecologic Pathology, Director of the Oncologic Surgical Pathology Fellowship Program, and Professor of Oncologic Sciences at USF. Dr. Hakam earned his medical degree at the Universidad Eugenio Maria de Hostos School of Medicine in Puerto Rico. He completed his residency at the University of Hawaii School of Medicine and completed three fellowships: one in genitourinary and gastrointestinal pathology at the University of Pittsburgh Medical Center in PA, and two (oncologic surgical pathology and cytopathology) at the University of South Florida. Dr. Hakam is board certified in cytopathology.


Education & Training

Board Certification:

  • Anatomic Pathology - Cytopathology

Fellowship:

  • University of Pittsburgh Medical Center, Pittsburgh, PA - Genitourinary & Gastrointestinal
  • University of South Florida - Oncologic Surgical Pathology
  • University of South Florida - Cytopathology

Residency:

  • University of Hawaii School of Medicine - Pathology

Medical School:

  • Universidad Eugenio Maria de Hostos School of Medicine - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath Iii CA, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L. NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022. J Natl Compr Canc Ne. 2022 Sep.20(9):972-980. Pubmedid: 36075393.
  • Tarhini AA, Hanayneh WB, Powers JJ, Segura CMM, Conejo-Garcia JR, Lam CA, Hakam A, Hoffman MS. Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanoma. Front Oncol. 2022 Nov.12:1044587. Pubmedid: 36531031. Pmcid: PMC9748561.
  • Martin AL, Sinha S, Peres LC, Hakam A, Chon HS, Hoffman MS, Shahzad MM, Wenham RM, Chern JY. The impact of distance to closest negative margin on survival after pelvic exenteration. Gynecol Oncol. 2022 Jun.165(3):514-521. Pubmedid: 35487774.
  • Lam C, Ha K, Hakam A, Shahzad MMK. Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism. Gynecol Oncol Rep. 2022 Jun.41:100992. Pubmedid: 35540026. Pmcid: PMC9079239.
  • Saeed-Vafa D, Marchion DC, McCarthy SM, Hakam A, Lopez A, Wenham RM, Apte SM, Chen DT, Magliocco AM, Lancaster JM, Reid BM, Permuth JB. Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomes. PLoS One. 2021 Nov.16(11):e0256615. Pubmedid: 34813586. Pmcid: PMC8610269.
  • Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2021 Feb.19(2):191-226. Pubmedid: 33545690.
  • Nguyen L, Khazai L, Hakam A, Centeno BA, Rosa M. Diagnostic value of intraoperative rapid cytokeratin immunostain in the cytological evaluation of sentinel lymph nodes in patients with invasive lobular carcinoma. Diagn Cytopathol. 2019 May.47(5):482-487. Pubmedid: 30589516.
  • Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA, Liu J, Mahdi H, Matei D, McHale M, McLean K, O'Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Canc Ne. 2019 Aug.17(8):896-909. Pubmedid: 31390583.
  • Matsuo K, Takazawa Y, Ross MS, Elishaev E, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Yanai S, Takeuchi S, Nishimura M, Iwasaki K, Johnson MS, Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Pejovic T, Nagano T, Sasaki T, Richmond AM, Post MD, Shahzad MMK, Im DD, Yoshida H, Enomoto T, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD. Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma. Ann Surg Oncol. 2018 Sep.25(9):2756-2766. Pubmedid: 29971677. Pmcid: PMC7523233.
  • Matsuo K, Takazawa Y, Ross MS, Elishaev E, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Yanai S, Takeuchi S, Nishimura M, Iwasaki K, Johnson MS, Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Pejovic T, Nagano T, Sasaki T, Richmond AM, Post MD, Shahzad MMK, Im DD, Yoshida H, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD. Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element. Surg Oncol. 2018 Sep.27(3):433-440. Pubmedid: 30217299. Pmcid: PMC7526039.
  • Matsuo K, Takazawa Y, Ross MS, Elishaev E, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Yanai S, Takeuchi S, Nishimura M, Iwasaki K, Johnson MS, Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Pejovic T, Nagano T, Sasaki T, Richmond AM, Post MD, Shahzad MMK, Im DD, Yoshida H, Enomoto T, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD. Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma. Ann Surg Oncol. 2018 Nov.25(12):3676-3684. Pubmedid: 30105438. Pmcid: PMC7521084.
  • Jeong D, Hakam A, Abuel-Haija M, Chon HS. Ovarian microcystic stromal tumor: Radiologic-pathologic correlation. Gynecol Oncol Rep. 2018 Aug.25:11-14. Pubmedid: 30014019. Pmcid: PMC6019857.
  • Kuznicki ML, Robertson SE, Hakam A, Shahzad MM. Metastatic uterine tumor resembling ovarian sex cord tumor: A case report and review of the literature. Gynecol Oncol Rep. 2017 Nov.22:64-68. Pubmedid: 29034309. Pmcid: PMC5633755.
  • Saglam O, Xiong Y, Marchion DC, Strosberg C, Wenham RM, Johnson JJ, Saeed-Vafa D, Cubitt C, Hakam A, Magliocco AM. ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy. Cancer Control. 2017 Jan.24(1):89-95. Pubmedid: 28178720. Pmcid: PMC7771303.
  • Morgan RJ, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Percac-Lima S, Pineda M, Plaxe SC, Powell MA, Ratner E, Remmenga SW, Rose PG, Sabbatini P, Santoso JT, Werner TL, Burns J, Hughes M. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2016 Sep.14(9):1134-1163. Pubmedid: 27587625.
  • Black M, Hakam A, Harris C, Jiang K. Metastatic breast carcinoma uncovered in an otherwise unremarkable “random colon biopsy”. Human Pathology: Case Reports. 2016 Jun.4:23-31.
  • Matsuo K, Takazawa Y, Ross MS, Elishaev E, Podzielinski I, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Matsuzaki S, Baba T, Satoh S, Shida M, Nishikawa T, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Fujiwara K, Hazama Y, Kadogami D, Moffitt MN, Takeuchi S, Nishimura M, Iwasaki K, Ushioda N, Johnson MS, Yoshida M, Hakam A, Li SW, Richmond AM, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Yamaguchi K, Oishi T, Kajiwara H, Hasegawa K, Yasuda M, Kawana K, Suda K, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Wakatsuki A, Sugiyama T, Pejovic T, Nagano T, Shimoya K, Andoh M, Shiki Y, Enomoto T, Sasaki T, Fujiwara K, Mikami M, Shimada M, Konishi I, Kimura T, Post MD, Shahzad MM, Im DD, Yoshida H, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD. Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. Ann Oncol. 2016 Jul.27(7):1257-1266. Pubmedid: 27052653.
  • Ahdallah R, Morse B, Hakam A, Shahzad MM. Pelvic squamous cell carcinoma of unknown primary: a case report and review of the literature. Eur J Gynaecol Oncol. 2016 Jul.37(3):430-433. Pubmedid: 27352581.
  • Hembree TN, Teer JK, Hakam A, Chiappori AA. Genetic Investigation of Uterine Carcinosarcoma: Case Report and Cohort Analysis. Cancer Control. 2016 Jan.23(1):61-66. Pubmedid: 27009459.
  • Siegel EM, Riggs BM, Delmas AL, Koch A, Hakam A, Brown KD. Quantitative DNA methylation analysis of candidate genes in cervical cancer. PLoS One. 2015 Mar.10(3):e0122495. Pubmedid: 25826459. Pmcid: PMC4380427.
  • Sawah EA, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Boac BM, Bush SH, Zgheib NB, McClung EC, Khulpateea BR, Berry A, Hakam A, Wenham RM, Lancaster JM, Judson PL. The Chinese herb polyphyllin D sensitizes ovarian cancer cells to cisplatin-induced growth arrest. J Cancer Res Clin Oncol. 2015 Feb.141(2):237-242. Pubmedid: 25164128.
  • Stickles XB, Marchion DC, Bicaku E, Al Sawah E, Abbasi F, Xiong Y, Bou Zgheib N, Boac BM, Orr BC, Judson PL, Berry A, Hakam A, Wenham RM, Apte SM, Berglund AE, Lancaster JM. BAD-mediated apoptotic pathway is associated with human cancer development. Int J Mol Med. 2015 Apr.35(4):1081-1087. Pubmedid: 25653146. Pmcid: PMC4356438.
  • Chen N, Chon HS, Xiong Y, Marchion DC, Judson PL, Hakam A, Gonzalez-Bosquet J, Permuth-Wey J, Wenham RM, Apte SM, Cheng JQ, Sellers TA, Lancaster JM. Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncol Rep. 2014 Jan.31(1):376-383. Pubmedid: 24220856. Pmcid: PMC3981115.
  • Carastro LM, Lin HY, Park HY, Kim D, Radlein S, Hampton KK, Hakam A, Zachariah B, Pow-Sang J, Park JY. Role of p73 Dinucleotide Polymorphism in Prostate Cancer and p73 Protein Isoform Balance. Prostate Cancer. 2014 Aug.2014:129582. Pubmedid: 25097786. Pmcid: PMC4109114.
  • Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M. Ovarian cancer, version 2.2013. J Natl Compr Canc Ne. 2013 Oct.11(10):1199-1209. Pubmedid: 24142821.
  • Amankwah EK, Anegbe E, Park H, Pow-Sang J, Hakam A, Park JY. miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases. Asian J Androl. 2013 Mar.15(2):226-230. Pubmedid: 23353719. Pmcid: PMC3705740.
  • Abdelbaqi M, Shackelford RE, Quigley BC, Hakam A. Concurrent Paget's disease and basal cell carcinoma of the vulva; a case report. Int J Clin Exp Pathol. 2013 Jan.5(6):592-595. Pubmedid: 22949943. Pmcid: PMC3430110.
  • Tahmasbi M, Nguyen J, Ghayouri M, Shan Y, Hakam A. Primary uterine cervix schwannoma: a case report and review of the literature. Case Rep Pathol. 2013 Jan.2012:353049. Pubmedid: 23320233. Pmcid: PMC3539385.
  • Setoodeh R, Hakam A, Shan Y. Cerebral metastasis of cervical cancer, report of two cases and review of the literature. Int J Clin Exp Pathol. 2013 Feb.5(7):710-714. Pubmedid: 22977669. Pmcid: PMC3438762.
  • Marchion DC, Xiong Y, Chon HS, Sawah EA, Zgheib NB, Ramirez IJ, Abbasi F, Stickles XB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund AE, Lancaster JM. Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer. Am J Obstet Gynecol. 2013 Dec.209(6):576.e1-576.e16. Pubmedid: 23933223. Pmcid: PMC3840156.
  • McNab P, Quigley B, Mendoza T, Hakam A, Khalil F, Fishman M, Altiok S. The histogenic origin of melanoma arising in respiratory epithelium of a teratomatous germ cell tumor of the mediastinum: an enigma unraveled from an unlikely source. Int J Clin Exp Pathol. 2013 Apr.5(9):982-990. Pubmedid: 23119117. Pmcid: PMC3484497.
  • House JC, Henderson-Jackson EB, Johnson JO, Lloyd MC, Dhillon J, Ahmad N, Hakam A, Khalbuss WE, Leon ME, Chhieng D, Zhang X, Centeno BA, Bui MM. Diagnostic digital cytopathology: Are we ready yet?. J Pathol Inform. 2013.4:28. Pubmedid: 24392242. Pmcid: PMC3869956.
  • Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA. Ovarian cancer, version 3.2012. J Natl Compr Canc Ne. 2012 Nov.10(11):1339-1349. Pubmedid: 23138163.
  • Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT, Lancaster JM. In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Brit J Cancer. 2012 Jun.106(12):1967-1975. Pubmedid: 22596241. Pmcid: PMC3388569.
  • Kumar NB, Vadaparampil ST, Mahajan N, Lilienfeld HS, Lee JH, Laronga C, Hakam A, Hein JJ, Egan KM, Arun B, Pal T. Metformin- A Promising Agent for Chemoprevention in BRCA1 Carriers. Hereditary Genet. 2012 Jun.1(2). Pubmedid: 26097796. Pmcid: PMC4474476.
  • Zgheib NB, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster JM. The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. Int J Oncol. 2012 Jul.41(1):179-188. Pubmedid: 22552627. Pmcid: PMC4017641.
  • Judson PL, Al Sawah E, Marchion DC, Xiong Y, Bicaku E, Zgheib NB, Chon HS, Stickles XB, Hakam A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Chen DT, Lancaster JM. Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity. Int J Gynecol Cancer. 2012 Jul.22(6):960-967. Pubmedid: 22740002. Pmcid: PMC4036555.
  • Chon HS, Marchion DC, Xiong Y, Chen N, Bicaku E, Stickles XB, Zgheib NB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Lancaster JM. The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Gynecol Oncol. 2012 Jan.124(1):119-124. Pubmedid: 22032837. Pmcid: PMC8744065.
  • Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, Sawah EA, Wenham RM, Apte SM, Gonzalez-Bosquet J, Judson PL, Hakam A, Lancaster JM. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. J Gynecol Oncol. 2012 Jan.23(1):35-42. Pubmedid: 22355465. Pmcid: PMC3280065.
  • Ouban A, Hamdan H, Hakam A, Ahmed AA. Claudin-1 expression in squamous cell carcinomas of different organs: comparative study of cancerous tissues and normal controls. Int J Surg Pathol. 2012 Apr.20(2):132-138. Pubmedid: 21997594.
  • Henderson-Jackson E, Sexton W, Zhang J, Hakam A, Petrovskyy VS, Bui MM, Chuang ST. Cystic prostatic ductal adenocarcinoma: an unusual presentation and cytological diagnosis. Ann Clin Lab Sci. 2012.42(1):81-88. Pubmedid: 22371914.
  • Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ, Shibata D. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 2011 Sep.10(3):188-193. Pubmedid: 21855041. Pmcid: PMC5726509.
  • Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster JM. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res. 2011 Oct.17(19):6356-6366. Pubmedid: 21849418. Pmcid: PMC3186862.
  • Delmas AL, Riggs BM, Pardo CE, Dyer LM, Darst RP, Izumchenko EG, Monroe M, Hakam A, Kladde MP, Siegel EM, Brown KD. WIF1 is a frequent target for epigenetic silencing in squamous cell carcinoma of the cervix. Carcinogenesis. 2011 Nov.32(11):1625-1633. Pubmedid: 21873353. Pmcid: PMC3204350.
  • Nasir A, Helm J, Turner L, Chen DT, Strosberg J, Hafez N, Henderson-Jackson EB, Hodul P, Bui MM, Nasir NA, Hakam A, Malafa MP, Yeatman TJ, Coppola D, Kvols LK. RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasms. Pancreas. 2011 May.40(4):627-633. Pubmedid: 21499216. Pmcid: PMC4732279.
  • Morgan RJ, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL. Epithelial ovarian cancer. J Natl Compr Canc Ne. 2011 Jan.9(1):82-113. Pubmedid: 21233246.
  • Tan PH, Cheng L, Srigley JR, Griffiths D, Humphrey PA, van der Kwast TH, Montironi R, Wheeler TM, Delahunt B, Egevad L, Epstein JI, Hakam A. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Mod Pathol. 2011 Jan.24(1):48-57. Pubmedid: 20729812.
  • Magi-Galluzzi C, Evans AJ, Delahunt B, Epstein JI, Griffiths DF, van der Kwast TH, Montironi R, Wheeler TM, Srigley JR, Egevad LL, Humphrey PA, Hakam A. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Mod Pathol. 2011 Jan.24(1):26-38. Pubmedid: 20802467.
  • Samaratunga H, Montironi R, True L, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Wheeler TM, Srigley JR, Delahunt B, Egevad L, Hakam A. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Mod Pathol. 2011 Jan.24(1):6-15. Pubmedid: 20834234.
  • van der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths D, Humphrey PA, Montironi R, Wheeler TM, Srigley JR, Egevad L, Delahunt B, Hakam A. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol. 2011 Jan.24(1):16-25. Pubmedid: 20818340.
  • Berney DM, Wheeler TM, Grignon DJ, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Montironi R, Delahunt B, Egevad L, Srigley JR, Hakam A. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Mod Pathol. 2011 Jan.24(1):39-47. Pubmedid: 20818343.
  • Bui MM, Purohit CN, Hakam A. Fine needle aspiration biopsy of an osteoclast-rich undifferentiated urothelial carcinoma: A cytology case report and review of the literature. Cytojournal. 2010 Sep.7:18. Pubmedid: 20976205. Pmcid: PMC2955341.
  • Henderson-Jackson EB, Helm J, Ghayouri M, Hakam A, Nasir A, Leon M, Bui M, Yeatman T, Coppola D. Correlation between Mcl-1 and pAKT protein expression in colorectal cancer. Int J Clin Exp Pathol. 2010 Oct.3(8):768-774. Pubmedid: 21151390. Pmcid: PMC2993227.
  • Riddle ND, Gorden L, Rojiani MV, Hakam A, Rojiani AM. CD44 and p53 immunoexpression patterns in NF1 neoplasms - indicators of malignancy and infiltration. Int J Clin Exp Pathol. 2010 Jun.3(5):515-521. Pubmedid: 20606732. Pmcid: PMC2897111.
  • Shackelford RE, Bui MM, Coppola D, Hakam A. Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers. Int J Clin Exp Pathol. 2010 Jun.3(5):522-527. Pubmedid: 20606733. Pmcid: PMC2897104.
  • Allam-Nandyala P, Bui MM, Caracciolo JT, Hakam A. Squamous cell carcinoma and osteosarcoma arising from a dermoid cyst--a case report and review of literature. Int J Clin Exp Pathol. 2010 Jan.3(3):313-318. Pubmedid: 20224730. Pmcid: PMC2836509.
  • Indermaur MD, Xiong Y, Kamath SG, Boren T, Hakam A, Wenham RM, Apte SM, Lancaster JM. Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin. Am J Obstet Gynecol. 2010 Aug.203(2):158.e1-158.40. Pubmedid: 20444440.
  • Henderson-Jackson E, Nasir NA, Hakam A, Nasir A, Coppola D. Primary mixed lymphoepithelioma-like carcinoma and intra-hepatic cholangiocarcinoma: a case report and review of literature. Int J Clin Exp Pathol. 2010 Aug.3(7):736-741. Pubmedid: 20830246. Pmcid: PMC2933395.
  • Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, Kamath SG, Chen DT, Dressman H, Lancaster JM. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol. 2009 May.113(2):249-255. Pubmedid: 19237188.
  • Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen D, Dressman H, Lancaster J. MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol. 2008 Aug.110(2):206-215. Pubmedid: 18499237.
  • Hoffman M, Williams V, Salihu H, Gunasekaran S, Sayer R, Hakam A, RobertsWS. The vascular portion of the cardinal ligament: surgical significance during radical hysterectomy for cervical cancer. Am J Obstet Gynecol. 2008 Aug.199(2):191.e1-191.e7. Pubmedid: 18554569.
  • Reed J, Hakam A, Nicosia S, Coppola D. Significance of Fas receptor protein expression in epithelial ovarian cancer. Hum Pathol. 2005 Sep.36(9):971-976. Pubmedid: 16153459.
  • Cox C, Centeno B, Dickson D, Clark J, Nicosia S, Dupont E, Greenberg H, Stowell N, White L, Patel J, Furman B, Cantor A, Hakam A, Ahmad N, Diaz N, King J. Accuracy of intraoperative imprint cytology for sentinel lymph node evaluation in the treatment of breast carcinoma. Cancer. 2005 Feb.105(1):13-20. Pubmedid: 15605359.
  • Hakam A, Khin NN. Intraoperative imprint cytology in assessment of sentinel lymph nodes and lumpectomy surgical margins. Clin Lab Med. 2005 Dec.25(4):795-807, viii. Pubmedid: 16308093.
  • Bodey V, Body V, Siegel S, Nasir A, Coppola D, Hakam A, Kaiser H. Immunocytochemical detection of members of the caspase cascade of apoptosis in high-grade astrocytomas. In Vivo. 2004 Sep.18(5):593-602. Pubmedid: 15523899.
  • Weinberg ES, Dickson D, White L, Ahmad N, Patel J, Hakam A, Nicosia S, Dupont E, Furman B, Centeno B, Cox C. Cytokeratin staining for intraoperative evaluation of sentinel lymph nodes in patients with invasive lobular carcinoma. Am J Surg. 2004 Oct.188(4):419-422. Pubmedid: 15474439.
  • Nasir A, Kaiser H, Boulware D, Hakam A, Zhao H, Yeatman T, Barthel J, Coppola D. Cyclooxygenase-2 expression in right- and left-sided colon cancer: a rationale for optimization of cyclooxygenase-2 inhibitor therapy. Clin Colorectal Cancer. 2004 Feb.3(4):243-247. Pubmedid: 15025797.
  • Hakam A, Fang Q, Karl R, Coppola D. Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Digest Dis Sci. 2003 Oct.48(10):1972-1978. Pubmedid: 14627343.
  • Cardosi R, Speights A, Fiorica J, Grendys, Jr. E, Hakam A, Hoffman M. Bartholin's gland carcinoma: a 15-year experience. Gynecol Oncol. 2001 Aug.82(2):247-251. Pubmedid: 11531274.
  • Hakam A, Yeatman T, Lu L, Mora L, Marcet J, Nicosia S, Karl R, Coppola D. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol. 1999 Oct.30(10):1128-1133. Pubmedid: 10534157.
  • Diaz J, Mora L, Hakam A. The Mainz Classification of Renal Cell Tumors. Cancer Control. 1999 Nov.6(6):571-579. Pubmedid: 10756388.
  • Getzenberg RH, Konety BR, Oeler TA, Quigley MM, Hakam A, Becich MJ, Bahnson PR. Bladder Cancer-associated Nuclear Matrix proteins. Cancer Res. 1996.56(7):1690-1694. Pubmedid: 8603421.
  • Hakam A, Nasir A, Raghuwanshi R, Smith P, Crawley S, Kaiser H, Grendys E, Fiorica J. Value of multilevel sectioning for improved detection of micrometastases in sentinel lymph nodes in invasive squamous cell carcinoma of the vulva. Anticancer Res. 24(2C):1281-1286. Pubmedid: 15154661.
  • Nasir A, Boulware D, Kaiser H, Lancaster J, Coppola D, Smith P, Hakam A, Siegel S, Bodey B. Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy. In Vivo. 21(1):35-43. Pubmedid: 17354612.

Patient Comments
Overall Satisfaction
0
★★★★★
★★★★★

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments